id	sid	tid	token	lemma	pos
dpc-2908	1	1	dermatology	dermatology	NOUN
dpc-2908	1	2	:	:	PUNCT
dpc-2908	1	3	practical	practical	ADJ
dpc-2908	1	4	and	and	CCONJ
dpc-2908	1	5	conceptual	conceptual	ADJ
dpc-2908	1	6	letter	letter	NOUN
dpc-2908	1	7	to	to	ADP
dpc-2908	1	8	the	the	DET
dpc-2908	1	9	editor	editor	NOUN
dpc-2908	1	10	|	|	ADV
dpc-2908	1	11	dermatol	dermatol	ADJ
dpc-2908	1	12	pract	pract	NOUN
dpc-2908	1	13	concept	concept	NOUN
dpc-2908	1	14	.	.	PUNCT
dpc-2908	2	1	2023;13(3):e2023178	2023;13(3):e2023178	NUM
dpc-2908	2	2	1	1	NUM
dpc-2908	2	3	efficacy	efficacy	NOUN
dpc-2908	2	4	of	of	ADP
dpc-2908	2	5	cemiplimab	cemiplimab	NOUN
dpc-2908	2	6	in	in	ADP
dpc-2908	2	7	a	a	DET
dpc-2908	2	8	patient	patient	NOUN
dpc-2908	2	9	affected	affect	VERB
dpc-2908	2	10	by	by	ADP
dpc-2908	2	11	cutaneous	cutaneous	ADJ
dpc-2908	2	12	squamous	squamous	ADJ
dpc-2908	2	13	cell	cell	NOUN
dpc-2908	2	14	carcinoma	carcinoma	NOUN
dpc-2908	2	15	and	and	CCONJ
dpc-2908	2	16	 	 	SPACE
dpc-2908	2	17	myelodysplastic	myelodysplastic	ADJ
dpc-2908	2	18	syndrome	syndrome	NOUN
dpc-2908	2	19	ilaria	ilaria	PROPN
dpc-2908	2	20	proietti1	proietti1	PROPN
dpc-2908	2	21	,	,	PUNCT
dpc-2908	2	22	ersilia	ersilia	PROPN
dpc-2908	2	23	tolino1	tolino1	PROPN
dpc-2908	2	24	,	,	PUNCT
dpc-2908	2	25	nicoletta	nicoletta	PROPN
dpc-2908	2	26	bernardini1	bernardini1	PROPN
dpc-2908	2	27	,	,	PUNCT
dpc-2908	2	28	marco	marco	PROPN
dpc-2908	2	29	di	di	PROPN
dpc-2908	2	30	fraia1	fraia1	PROPN
dpc-2908	2	31	,	,	PUNCT
dpc-2908	2	32	nevena	nevena	PROPN
dpc-2908	2	33	skroza1	skroza1	PROPN
dpc-2908	2	34	,	,	PUNCT
dpc-2908	2	35	concetta	concetta	PROPN
dpc-2908	2	36	potenza1	potenza1	NOUN
dpc-2908	2	37	1	1	NUM
dpc-2908	2	38	department	department	NOUN
dpc-2908	2	39	of	of	ADP
dpc-2908	2	40	medico	medico	PROPN
dpc-2908	2	41	-	-	PUNCT
dpc-2908	2	42	surgical	surgical	ADJ
dpc-2908	2	43	sciences	science	NOUN
dpc-2908	2	44	and	and	CCONJ
dpc-2908	2	45	biotechnologies	biotechnology	NOUN
dpc-2908	2	46	,	,	PUNCT
dpc-2908	2	47	polo	polo	NOUN
dpc-2908	2	48	pontino	pontino	NOUN
dpc-2908	2	49	,	,	PUNCT
dpc-2908	2	50	sapienza	sapienza	PROPN
dpc-2908	2	51	university	university	PROPN
dpc-2908	2	52	of	of	ADP
dpc-2908	2	53	rome	rome	PROPN
dpc-2908	2	54	,	,	PUNCT
dpc-2908	2	55	italy	italy	PROPN
dpc-2908	2	56	citation	citation	PROPN
dpc-2908	2	57	:	:	PUNCT
dpc-2908	2	58	proietti	proietti	NOUN
dpc-2908	2	59	i	i	PRON
dpc-2908	2	60	,	,	PUNCT
dpc-2908	2	61	tolino	tolino	NOUN
dpc-2908	2	62	e	e	PROPN
dpc-2908	2	63	,	,	PUNCT
dpc-2908	2	64	bernardini	bernardini	PROPN
dpc-2908	2	65	n	n	CCONJ
dpc-2908	2	66	,	,	PUNCT
dpc-2908	2	67	di	di	PROPN
dpc-2908	2	68	fraia	fraia	PROPN
dpc-2908	2	69	m	m	PROPN
dpc-2908	2	70	,	,	PUNCT
dpc-2908	2	71	skroza	skroza	PROPN
dpc-2908	2	72	n	n	CCONJ
dpc-2908	2	73	,	,	PUNCT
dpc-2908	2	74	potenza	potenza	PROPN
dpc-2908	2	75	c.	c.	PROPN
dpc-2908	2	76	efficacy	efficacy	PROPN
dpc-2908	2	77	of	of	ADP
dpc-2908	2	78	cemiplimab	cemiplimab	NOUN
dpc-2908	2	79	in	in	ADP
dpc-2908	2	80	a	a	DET
dpc-2908	2	81	patient	patient	NOUN
dpc-2908	2	82	affected	affect	VERB
dpc-2908	2	83	by	by	ADP
dpc-2908	2	84	cutaneous	cutaneous	ADJ
dpc-2908	2	85	squamous	squamous	ADJ
dpc-2908	2	86	cell	cell	NOUN
dpc-2908	2	87	carcinoma	carcinoma	NOUN
dpc-2908	2	88	and	and	CCONJ
dpc-2908	2	89	myelodysplastic	myelodysplastic	ADJ
dpc-2908	2	90	syndrome	syndrome	NOUN
dpc-2908	2	91	.	.	PUNCT
dpc-2908	3	1	dermatol	dermatol	NOUN
dpc-2908	3	2	pract	pract	PROPN
dpc-2908	3	3	concept	concept	NOUN
dpc-2908	3	4	.	.	PUNCT
dpc-2908	4	1	2023;13(3):e2023178	2023;13(3):e2023178	X
dpc-2908	4	2	.	.	PUNCT
dpc-2908	4	3	doi	doi	PROPN
dpc-2908	4	4	:	:	PUNCT
dpc-2908	4	5	https://doi.org/10.5826/dpc.1303a178	https://doi.org/10.5826/dpc.1303a178	PROPN
dpc-2908	4	6	accepted	accept	VERB
dpc-2908	4	7	:	:	PUNCT
dpc-2908	4	8	february	february	PROPN
dpc-2908	4	9	28	28	NUM
dpc-2908	4	10	,	,	PUNCT
dpc-2908	4	11	2023	2023	NUM
dpc-2908	4	12	;	;	PUNCT
dpc-2908	4	13	published	publish	VERB
dpc-2908	4	14	:	:	PUNCT
dpc-2908	5	1	july	july	PROPN
dpc-2908	5	2	2023	2023	NUM
dpc-2908	5	3	copyright	copyright	NOUN
dpc-2908	5	4	:	:	PUNCT
dpc-2908	5	5	©	©	PROPN
dpc-2908	5	6	2023	2023	NUM
dpc-2908	5	7	proietti	proietti	NOUN
dpc-2908	5	8	et	et	NOUN
dpc-2908	5	9	al	al	PROPN
dpc-2908	5	10	.	.	PUNCT
dpc-2908	6	1	this	this	PRON
dpc-2908	6	2	is	be	AUX
dpc-2908	6	3	an	an	DET
dpc-2908	6	4	open	open	ADJ
dpc-2908	6	5	-	-	PUNCT
dpc-2908	6	6	access	access	NOUN
dpc-2908	6	7	article	article	NOUN
dpc-2908	6	8	distributed	distribute	VERB
dpc-2908	6	9	under	under	ADP
dpc-2908	6	10	the	the	DET
dpc-2908	6	11	terms	term	NOUN
dpc-2908	6	12	of	of	ADP
dpc-2908	6	13	the	the	DET
dpc-2908	6	14	creative	creative	ADJ
dpc-2908	6	15	commons	common	NOUN
dpc-2908	6	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-2908	6	17	license	license	NOUN
dpc-2908	6	18	(	(	PUNCT
dpc-2908	6	19	by	by	ADP
dpc-2908	6	20	-	-	PUNCT
dpc-2908	6	21	nc-4.0	nc-4.0	NOUN
dpc-2908	6	22	)	)	PUNCT
dpc-2908	6	23	,	,	PUNCT
dpc-2908	6	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2908	6	25	,	,	PUNCT
dpc-2908	6	26	which	which	PRON
dpc-2908	6	27	permits	permit	VERB
dpc-2908	6	28	unrestricted	unrestricted	ADJ
dpc-2908	6	29	noncommercial	noncommercial	ADJ
dpc-2908	6	30	use	use	NOUN
dpc-2908	6	31	,	,	PUNCT
dpc-2908	6	32	distribution	distribution	NOUN
dpc-2908	6	33	,	,	PUNCT
dpc-2908	6	34	and	and	CCONJ
dpc-2908	6	35	reproduction	reproduction	NOUN
dpc-2908	6	36	in	in	ADP
dpc-2908	6	37	any	any	DET
dpc-2908	6	38	medium	medium	NOUN
dpc-2908	6	39	,	,	PUNCT
dpc-2908	6	40	provided	provide	VERB
dpc-2908	6	41	the	the	DET
dpc-2908	6	42	original	original	ADJ
dpc-2908	6	43	authors	author	NOUN
dpc-2908	6	44	and	and	CCONJ
dpc-2908	6	45	source	source	NOUN
dpc-2908	6	46	are	be	AUX
dpc-2908	6	47	credited	credit	VERB
dpc-2908	6	48	.	.	PUNCT
dpc-2908	7	1	funding	funding	NOUN
dpc-2908	7	2	:	:	PUNCT
dpc-2908	7	3	none	none	NOUN
dpc-2908	7	4	.	.	PUNCT
dpc-2908	8	1	competing	compete	VERB
dpc-2908	8	2	interests	interest	NOUN
dpc-2908	8	3	:	:	PUNCT
dpc-2908	8	4	none	none	NOUN
dpc-2908	8	5	.	.	PUNCT
dpc-2908	9	1	authorship	authorship	NOUN
dpc-2908	9	2	:	:	PUNCT
dpc-2908	9	3	all	all	DET
dpc-2908	9	4	authors	author	NOUN
dpc-2908	9	5	have	have	AUX
dpc-2908	9	6	contributed	contribute	VERB
dpc-2908	9	7	significantly	significantly	ADV
dpc-2908	9	8	to	to	ADP
dpc-2908	9	9	this	this	DET
dpc-2908	9	10	publication	publication	NOUN
dpc-2908	9	11	.	.	PUNCT
dpc-2908	10	1	corresponding	correspond	VERB
dpc-2908	10	2	author	author	NOUN
dpc-2908	10	3	:	:	PUNCT
dpc-2908	10	4	di	di	PROPN
dpc-2908	10	5	fraia	fraia	PROPN
dpc-2908	10	6	marco	marco	PROPN
dpc-2908	10	7	,	,	PUNCT
dpc-2908	10	8	md	md	PROPN
dpc-2908	10	9	,	,	PUNCT
dpc-2908	10	10	department	department	PROPN
dpc-2908	10	11	of	of	ADP
dpc-2908	10	12	medico	medico	PROPN
dpc-2908	10	13	-	-	PUNCT
dpc-2908	10	14	surgical	surgical	ADJ
dpc-2908	10	15	sciences	science	NOUN
dpc-2908	10	16	and	and	CCONJ
dpc-2908	10	17	biotechnologies	biotechnology	NOUN
dpc-2908	10	18	,	,	PUNCT
dpc-2908	10	19	polo	polo	NOUN
dpc-2908	10	20	pontino	pontino	NOUN
dpc-2908	10	21	,	,	PUNCT
dpc-2908	10	22	sapienza	sapienza	PROPN
dpc-2908	10	23	university	university	PROPN
dpc-2908	10	24	of	of	ADP
dpc-2908	10	25	rome	rome	PROPN
dpc-2908	10	26	,	,	PUNCT
dpc-2908	10	27	corso	corso	PROPN
dpc-2908	10	28	della	della	PROPN
dpc-2908	10	29	repubblica	repubblica	PROPN
dpc-2908	10	30	,	,	PUNCT
dpc-2908	10	31	79	79	NUM
dpc-2908	10	32	,	,	PUNCT
dpc-2908	10	33	04100	04100	NUM
dpc-2908	10	34	,	,	PUNCT
dpc-2908	10	35	latina	latina	ADJ
dpc-2908	10	36	(	(	PUNCT
dpc-2908	10	37	lt	lt	NOUN
dpc-2908	10	38	)	)	PUNCT
dpc-2908	10	39	,	,	PUNCT
dpc-2908	10	40	italy	italy	PROPN
dpc-2908	10	41	.	.	PUNCT
dpc-2908	11	1	e	e	X
dpc-2908	11	2	-	-	NOUN
dpc-2908	11	3	mail	mail	NOUN
dpc-2908	11	4	:	:	PUNCT
dpc-2908	11	5	marco.difraia@uniroma1.it	marco.difraia@uniroma1.it	NOUN
dpc-2908	11	6	dear	dear	ADJ
dpc-2908	11	7	editor	editor	NOUN
dpc-2908	11	8	,	,	PUNCT
dpc-2908	11	9	we	we	PRON
dpc-2908	11	10	have	have	AUX
dpc-2908	11	11	read	read	VERB
dpc-2908	11	12	with	with	ADP
dpc-2908	11	13	interest	interest	NOUN
dpc-2908	11	14	the	the	DET
dpc-2908	11	15	article	article	NOUN
dpc-2908	11	16	by	by	ADP
dpc-2908	11	17	michela	michela	PROPN
dpc-2908	11	18	lai	lai	PROPN
dpc-2908	11	19	et	et	PROPN
dpc-2908	11	20	al	al	PROPN
dpc-2908	11	21	entitled	entitle	VERB
dpc-2908	11	22	“	"	PUNCT
dpc-2908	11	23	cutaneous	cutaneous	ADJ
dpc-2908	11	24	squamous	squamous	ADJ
dpc-2908	11	25	cell	cell	NOUN
dpc-2908	11	26	carcinoma	carcinoma	NOUN
dpc-2908	11	27	in	in	ADP
dpc-2908	11	28	patients	patient	NOUN
dpc-2908	11	29	with	with	ADP
dpc-2908	11	30	chronic	chronic	ADJ
dpc-2908	11	31	lymphocytic	lymphocytic	ADJ
dpc-2908	11	32	leukemia	leukemia	NOUN
dpc-2908	11	33	:	:	PUNCT
dpc-2908	11	34	a	a	DET
dpc-2908	11	35	systematic	systematic	ADJ
dpc-2908	11	36	review	review	NOUN
dpc-2908	11	37	of	of	ADP
dpc-2908	11	38	the	the	DET
dpc-2908	11	39	literature	literature	NOUN
dpc-2908	11	40	”	"	PUNCT
dpc-2908	12	1	[	[	X
dpc-2908	12	2	1	1	NUM
dpc-2908	12	3	]	]	PUNCT
dpc-2908	12	4	.	.	PUNCT
dpc-2908	13	1	cutaneous	cutaneous	ADJ
dpc-2908	13	2	squamous	squamous	ADJ
dpc-2908	13	3	cell	cell	NOUN
dpc-2908	13	4	carcinoma	carcinoma	NOUN
dpc-2908	13	5	(	(	PUNCT
dpc-2908	13	6	cscc	cscc	ADJ
dpc-2908	13	7	)	)	PUNCT
dpc-2908	13	8	is	be	AUX
dpc-2908	13	9	the	the	DET
dpc-2908	13	10	second	second	ADJ
dpc-2908	13	11	most	most	ADV
dpc-2908	13	12	common	common	ADJ
dpc-2908	13	13	malignant	malignant	ADJ
dpc-2908	13	14	neoplasm	neoplasm	NOUN
dpc-2908	13	15	of	of	ADP
dpc-2908	13	16	the	the	DET
dpc-2908	13	17	skin	skin	NOUN
dpc-2908	13	18	.	.	PUNCT
dpc-2908	14	1	immunosuppressed	immunosuppressed	ADJ
dpc-2908	14	2	patients	patient	NOUN
dpc-2908	14	3	can	can	AUX
dpc-2908	14	4	develop	develop	VERB
dpc-2908	14	5	cscc	cscc	ADJ
dpc-2908	14	6	more	more	ADV
dpc-2908	14	7	frequently	frequently	ADV
dpc-2908	14	8	than	than	ADP
dpc-2908	14	9	average	average	ADJ
dpc-2908	14	10	population	population	NOUN
dpc-2908	14	11	,	,	PUNCT
dpc-2908	14	12	and	and	CCONJ
dpc-2908	14	13	these	these	DET
dpc-2908	14	14	cancers	cancer	NOUN
dpc-2908	14	15	seem	seem	VERB
dpc-2908	14	16	to	to	PART
dpc-2908	14	17	behave	behave	VERB
dpc-2908	14	18	more	more	ADV
dpc-2908	14	19	aggressively	aggressively	ADV
dpc-2908	14	20	with	with	ADP
dpc-2908	14	21	a	a	DET
dpc-2908	14	22	lower	low	ADJ
dpc-2908	14	23	degree	degree	NOUN
dpc-2908	14	24	of	of	ADP
dpc-2908	14	25	differentiation	differentiation	NOUN
dpc-2908	14	26	[	[	X
dpc-2908	14	27	2	2	NUM
dpc-2908	14	28	]	]	PUNCT
dpc-2908	14	29	.	.	PUNCT
dpc-2908	15	1	naturally	naturally	ADV
dpc-2908	15	2	,	,	PUNCT
dpc-2908	15	3	hematologic	hematologic	NOUN
dpc-2908	15	4	patients	patient	NOUN
dpc-2908	15	5	have	have	VERB
dpc-2908	15	6	an	an	DET
dpc-2908	15	7	immunosuppressed	immunosuppressed	ADJ
dpc-2908	15	8	status	status	NOUN
dpc-2908	15	9	due	due	ADP
dpc-2908	15	10	to	to	ADP
dpc-2908	15	11	their	their	PRON
dpc-2908	15	12	disease	disease	NOUN
dpc-2908	15	13	and	and	CCONJ
dpc-2908	15	14	to	to	ADP
dpc-2908	15	15	its	its	PRON
dpc-2908	15	16	treatment	treatment	NOUN
dpc-2908	15	17	.	.	PUNCT
dpc-2908	16	1	immunotherapy	immunotherapy	NOUN
dpc-2908	16	2	(	(	PUNCT
dpc-2908	16	3	it	it	PRON
dpc-2908	16	4	)	)	PUNCT
dpc-2908	16	5	is	be	AUX
dpc-2908	16	6	assuming	assume	VERB
dpc-2908	16	7	an	an	DET
dpc-2908	16	8	important	important	ADJ
dpc-2908	16	9	role	role	NOUN
dpc-2908	16	10	in	in	ADP
dpc-2908	16	11	the	the	DET
dpc-2908	16	12	treatment	treatment	NOUN
dpc-2908	16	13	of	of	ADP
dpc-2908	16	14	cscc	cscc	NOUN
dpc-2908	16	15	:	:	PUNCT
dpc-2908	16	16	cemiplimab	cemiplimab	NOUN
dpc-2908	16	17	,	,	PUNCT
dpc-2908	16	18	an	an	DET
dpc-2908	16	19	inhibitor	inhibitor	NOUN
dpc-2908	16	20	of	of	ADP
dpc-2908	16	21	programmed	program	VERB
dpc-2908	16	22	death	death	NOUN
dpc-2908	16	23	receptor-1	receptor-1	NUM
dpc-2908	16	24	(	(	PUNCT
dpc-2908	16	25	pd-1	pd-1	X
dpc-2908	16	26	)	)	PUNCT
dpc-2908	16	27	has	have	AUX
dpc-2908	16	28	been	be	AUX
dpc-2908	16	29	approved	approve	VERB
dpc-2908	16	30	for	for	ADP
dpc-2908	16	31	patients	patient	NOUN
dpc-2908	16	32	affected	affect	VERB
dpc-2908	16	33	by	by	ADP
dpc-2908	16	34	cscc	cscc	ADJ
dpc-2908	16	35	,	,	PUNCT
dpc-2908	16	36	not	not	PART
dpc-2908	16	37	eligible	eligible	ADJ
dpc-2908	16	38	to	to	PART
dpc-2908	16	39	curative	curative	ADJ
dpc-2908	16	40	surgery	surgery	NOUN
dpc-2908	16	41	and	and	CCONJ
dpc-2908	16	42	radiotherapy	radiotherapy	NOUN
dpc-2908	16	43	.	.	PUNCT
dpc-2908	17	1	however	however	ADV
dpc-2908	17	2	,	,	PUNCT
dpc-2908	17	3	the	the	DET
dpc-2908	17	4	use	use	NOUN
dpc-2908	17	5	of	of	ADP
dpc-2908	17	6	immunotherapy	immunotherapy	NOUN
dpc-2908	17	7	in	in	ADP
dpc-2908	17	8	hematologic	hematologic	NOUN
dpc-2908	17	9	patients	patient	NOUN
dpc-2908	17	10	with	with	ADP
dpc-2908	17	11	cscc	cscc	PROPN
dpc-2908	17	12	is	be	AUX
dpc-2908	17	13	still	still	ADV
dpc-2908	17	14	under	under	ADP
dpc-2908	17	15	study	study	NOUN
dpc-2908	17	16	,	,	PUNCT
dpc-2908	17	17	for	for	SCONJ
dpc-2908	17	18	this	this	DET
dpc-2908	17	19	population	population	NOUN
dpc-2908	17	20	is	be	AUX
dpc-2908	17	21	often	often	ADV
dpc-2908	17	22	excluded	exclude	VERB
dpc-2908	17	23	from	from	ADP
dpc-2908	17	24	clinical	clinical	ADJ
dpc-2908	17	25	trials	trial	NOUN
dpc-2908	17	26	[	[	X
dpc-2908	17	27	3	3	NUM
dpc-2908	17	28	]	]	PUNCT
dpc-2908	17	29	.	.	PUNCT
dpc-2908	18	1	herein	herein	NOUN
dpc-2908	18	2	we	we	PRON
dpc-2908	18	3	present	present	VERB
dpc-2908	18	4	the	the	DET
dpc-2908	18	5	case	case	NOUN
dpc-2908	18	6	of	of	ADP
dpc-2908	18	7	a	a	DET
dpc-2908	18	8	hematologic	hematologic	NOUN
dpc-2908	18	9	patient	patient	NOUN
dpc-2908	18	10	affected	affect	VERB
dpc-2908	18	11	by	by	ADP
dpc-2908	18	12	cscc	cscc	PROPN
dpc-2908	18	13	treated	treat	VERB
dpc-2908	18	14	with	with	ADP
dpc-2908	18	15	cemiplimab	cemiplimab	NOUN
dpc-2908	18	16	.	.	PUNCT
dpc-2908	19	1	a	a	DET
dpc-2908	19	2	73	73	NUM
dpc-2908	19	3	-	-	PUNCT
dpc-2908	19	4	year	year	NOUN
dpc-2908	19	5	-	-	PUNCT
dpc-2908	19	6	old	old	ADJ
dpc-2908	19	7	man	man	NOUN
dpc-2908	19	8	showed	show	VERB
dpc-2908	19	9	a	a	DET
dpc-2908	19	10	painful	painful	ADJ
dpc-2908	19	11	,	,	PUNCT
dpc-2908	19	12	ulcerated	ulcerated	ADJ
dpc-2908	19	13	firm	firm	ADJ
dpc-2908	19	14	nodule	nodule	NOUN
dpc-2908	19	15	of	of	ADP
dpc-2908	19	16	the	the	DET
dpc-2908	19	17	lower	low	ADJ
dpc-2908	19	18	left	left	ADJ
dpc-2908	19	19	hemilip	hemilip	NOUN
dpc-2908	19	20	(	(	PUNCT
dpc-2908	19	21	figure	figure	NOUN
dpc-2908	19	22	1a	1a	NOUN
dpc-2908	19	23	)	)	PUNCT
dpc-2908	19	24	and	and	CCONJ
dpc-2908	19	25	a	a	DET
dpc-2908	19	26	nodular	nodular	ADJ
dpc-2908	19	27	ulcerated	ulcerated	ADJ
dpc-2908	19	28	lesion	lesion	NOUN
dpc-2908	19	29	in	in	ADP
dpc-2908	19	30	the	the	DET
dpc-2908	19	31	submental	submental	ADJ
dpc-2908	19	32	region	region	NOUN
dpc-2908	19	33	(	(	PUNCT
dpc-2908	19	34	figure	figure	NOUN
dpc-2908	19	35	1b	1b	NUM
dpc-2908	19	36	)	)	PUNCT
dpc-2908	19	37	.	.	PUNCT
dpc-2908	20	1	the	the	DET
dpc-2908	20	2	patient	patient	NOUN
dpc-2908	20	3	also	also	ADV
dpc-2908	20	4	complained	complain	VERB
dpc-2908	20	5	about	about	ADP
dpc-2908	20	6	remarkable	remarkable	ADJ
dpc-2908	20	7	fatigue	fatigue	NOUN
dpc-2908	20	8	.	.	PUNCT
dpc-2908	21	1	he	he	PRON
dpc-2908	21	2	has	have	AUX
dpc-2908	21	3	been	be	AUX
dpc-2908	21	4	suffering	suffer	VERB
dpc-2908	21	5	from	from	ADP
dpc-2908	21	6	myelodysplastic	myelodysplastic	ADJ
dpc-2908	21	7	syndrome	syndrome	NOUN
dpc-2908	21	8	(	(	PUNCT
dpc-2908	21	9	mds	mds	PROPN
dpc-2908	21	10	)	)	PUNCT
dpc-2908	21	11	for	for	ADP
dpc-2908	21	12	around	around	ADP
dpc-2908	21	13	two	two	NUM
dpc-2908	21	14	years	year	NOUN
dpc-2908	21	15	.	.	PUNCT
dpc-2908	22	1	a	a	DET
dpc-2908	22	2	diagnosis	diagnosis	NOUN
dpc-2908	22	3	of	of	ADP
dpc-2908	22	4	a	a	DET
dpc-2908	22	5	type	type	NOUN
dpc-2908	22	6	2	2	NUM
dpc-2908	22	7	refractory	refractory	NOUN
dpc-2908	22	8	anemia	anemia	NOUN
dpc-2908	22	9	with	with	ADP
dpc-2908	22	10	excess	excess	NOUN
dpc-2908	22	11	of	of	ADP
dpc-2908	22	12	blasts	blast	NOUN
dpc-2908	22	13	(	(	PUNCT
dpc-2908	22	14	raeb-2	raeb-2	NUM
dpc-2908	22	15	)	)	PUNCT
dpc-2908	22	16	was	be	AUX
dpc-2908	22	17	made	make	VERB
dpc-2908	22	18	after	after	ADP
dpc-2908	22	19	bone	bone	NOUN
dpc-2908	22	20	marrow	marrow	NOUN
dpc-2908	22	21	aspiration	aspiration	NOUN
dpc-2908	22	22	(	(	PUNCT
dpc-2908	22	23	2016	2016	NUM
dpc-2908	22	24	who	who	PRON
dpc-2908	22	25	classification	classification	VERB
dpc-2908	22	26	)	)	PUNCT
dpc-2908	22	27	.	.	PUNCT
dpc-2908	23	1	the	the	DET
dpc-2908	23	2	patient	patient	NOUN
dpc-2908	23	3	was	be	AUX
dpc-2908	23	4	under	under	ADP
dpc-2908	23	5	treatment	treatment	NOUN
dpc-2908	23	6	with	with	ADP
dpc-2908	23	7	systemic	systemic	ADJ
dpc-2908	23	8	antibiotics	antibiotic	NOUN
dpc-2908	23	9	and	and	CCONJ
dpc-2908	23	10	5	5	NUM
dpc-2908	23	11	-	-	PUNCT
dpc-2908	23	12	azacytidine	azacytidine	NOUN
dpc-2908	23	13	.	.	PUNCT
dpc-2908	24	1	excisional	excisional	ADJ
dpc-2908	24	2	(	(	PUNCT
dpc-2908	24	3	free	free	ADJ
dpc-2908	24	4	margins	margin	NOUN
dpc-2908	24	5	)	)	PUNCT
dpc-2908	24	6	skin	skin	NOUN
dpc-2908	24	7	biopsy	biopsy	NOUN
dpc-2908	24	8	of	of	ADP
dpc-2908	24	9	the	the	DET
dpc-2908	24	10	labial	labial	ADJ
dpc-2908	24	11	lesion	lesion	NOUN
dpc-2908	24	12	revealed	reveal	VERB
dpc-2908	24	13	a	a	DET
dpc-2908	24	14	g3	g3	NOUN
dpc-2908	24	15	cscc	cscc	VERB
dpc-2908	24	16	,	,	PUNCT
dpc-2908	24	17	with	with	ADP
dpc-2908	24	18	skeletal	skeletal	ADJ
dpc-2908	24	19	muscle	muscle	NOUN
dpc-2908	24	20	and	and	CCONJ
dpc-2908	24	21	bone	bone	NOUN
dpc-2908	24	22	invasion	invasion	NOUN
dpc-2908	24	23	(	(	PUNCT
dpc-2908	24	24	pt3	pt3	NOUN
dpc-2908	24	25	according	accord	VERB
dpc-2908	24	26	to	to	ADP
dpc-2908	24	27	ajcc	ajcc	PROPN
dpc-2908	24	28	staging	staging	NOUN
dpc-2908	24	29	system	system	NOUN
dpc-2908	24	30	)	)	PUNCT
dpc-2908	24	31	.	.	PUNCT
dpc-2908	25	1	no	no	DET
dpc-2908	25	2	biopsy	biopsy	NOUN
dpc-2908	25	3	was	be	AUX
dpc-2908	25	4	performed	perform	VERB
dpc-2908	25	5	for	for	ADP
dpc-2908	25	6	the	the	DET
dpc-2908	25	7	ulcerated	ulcerated	ADJ
dpc-2908	25	8	lesion	lesion	NOUN
dpc-2908	25	9	of	of	ADP
dpc-2908	25	10	the	the	DET
dpc-2908	25	11	submental	submental	ADJ
dpc-2908	25	12	region	region	NOUN
dpc-2908	25	13	.	.	PUNCT
dpc-2908	26	1	the	the	DET
dpc-2908	26	2	patient	patient	NOUN
dpc-2908	26	3	underwent	undergo	VERB
dpc-2908	26	4	a	a	DET
dpc-2908	26	5	positron	positron	NOUN
dpc-2908	26	6	emission	emission	NOUN
dpc-2908	26	7	computed	compute	VERB
dpc-2908	26	8	2	2	NUM
dpc-2908	26	9	letter	letter	NOUN
dpc-2908	26	10	to	to	ADP
dpc-2908	26	11	the	the	DET
dpc-2908	26	12	editor	editor	NOUN
dpc-2908	26	13	|	|	ADV
dpc-2908	26	14	dermatol	dermatol	ADJ
dpc-2908	26	15	pract	pract	NOUN
dpc-2908	26	16	concept	concept	NOUN
dpc-2908	26	17	.	.	PUNCT
dpc-2908	27	1	2023;13(3):e2023178	2023;13(3):e2023178	NUM
dpc-2908	27	2	tomography	tomography	NOUN
dpc-2908	27	3	(	(	PUNCT
dpc-2908	27	4	pet	pet	NOUN
dpc-2908	27	5	/	/	SYM
dpc-2908	27	6	ct	ct	PROPN
dpc-2908	27	7	)	)	PUNCT
dpc-2908	27	8	with	with	ADP
dpc-2908	27	9	18	18	NUM
dpc-2908	27	10	-	-	PUNCT
dpc-2908	27	11	fluorodeoxyglucose	fluorodeoxyglucose	NOUN
dpc-2908	27	12	that	that	PRON
dpc-2908	27	13	showed	show	VERB
dpc-2908	27	14	two	two	NUM
dpc-2908	27	15	areas	area	NOUN
dpc-2908	27	16	of	of	ADP
dpc-2908	27	17	pathologic	pathologic	ADJ
dpc-2908	27	18	tracer	tracer	NOUN
dpc-2908	27	19	uptake	uptake	ADJ
dpc-2908	27	20	in	in	ADP
dpc-2908	27	21	the	the	DET
dpc-2908	27	22	lower	low	ADJ
dpc-2908	27	23	left	left	ADJ
dpc-2908	27	24	hemilip	hemilip	NOUN
dpc-2908	27	25	,	,	PUNCT
dpc-2908	27	26	extended	extend	VERB
dpc-2908	27	27	to	to	ADP
dpc-2908	27	28	the	the	DET
dpc-2908	27	29	jaw	jaw	NOUN
dpc-2908	27	30	,	,	PUNCT
dpc-2908	27	31	and	and	CCONJ
dpc-2908	27	32	in	in	ADP
dpc-2908	27	33	the	the	DET
dpc-2908	27	34	submental	submental	ADJ
dpc-2908	27	35	region	region	NOUN
dpc-2908	27	36	.	.	PUNCT
dpc-2908	28	1	in	in	ADP
dpc-2908	28	2	addition	addition	NOUN
dpc-2908	28	3	,	,	PUNCT
dpc-2908	28	4	the	the	DET
dpc-2908	28	5	exam	exam	NOUN
dpc-2908	28	6	documented	document	VERB
dpc-2908	28	7	mildly	mildly	ADV
dpc-2908	28	8	increased	increase	VERB
dpc-2908	28	9	tracer	tracer	NOUN
dpc-2908	28	10	uptake	uptake	ADJ
dpc-2908	28	11	in	in	ADP
dpc-2908	28	12	the	the	DET
dpc-2908	28	13	humeral	humeral	ADJ
dpc-2908	28	14	and	and	CCONJ
dpc-2908	28	15	femoral	femoral	ADJ
dpc-2908	28	16	diaphyses	diaphysis	NOUN
dpc-2908	28	17	,	,	PUNCT
dpc-2908	28	18	referable	referable	ADJ
dpc-2908	28	19	to	to	ADP
dpc-2908	28	20	the	the	DET
dpc-2908	28	21	mds	mds	NOUN
dpc-2908	28	22	,	,	PUNCT
dpc-2908	28	23	and	and	CCONJ
dpc-2908	28	24	some	some	DET
dpc-2908	28	25	pathologic	pathologic	ADJ
dpc-2908	28	26	cervical	cervical	ADJ
dpc-2908	28	27	adenopathies	adenopathy	NOUN
dpc-2908	28	28	.	.	PUNCT
dpc-2908	29	1	thus	thus	ADV
dpc-2908	29	2	,	,	PUNCT
dpc-2908	29	3	the	the	DET
dpc-2908	29	4	patient	patient	NOUN
dpc-2908	29	5	started	start	VERB
dpc-2908	29	6	treatment	treatment	NOUN
dpc-2908	29	7	with	with	ADP
dpc-2908	29	8	cemiplimab	cemiplimab	NOUN
dpc-2908	29	9	,	,	PUNCT
dpc-2908	29	10	350	350	NUM
dpc-2908	29	11	mg	mg	NOUN
dpc-2908	29	12	every	every	DET
dpc-2908	29	13	three	three	NUM
dpc-2908	29	14	weeks	week	NOUN
dpc-2908	29	15	.	.	PUNCT
dpc-2908	30	1	after	after	ADP
dpc-2908	30	2	five	five	NUM
dpc-2908	30	3	administrations	administration	NOUN
dpc-2908	30	4	,	,	PUNCT
dpc-2908	30	5	marked	mark	VERB
dpc-2908	30	6	clinical	clinical	ADJ
dpc-2908	30	7	improvement	improvement	NOUN
dpc-2908	30	8	of	of	ADP
dpc-2908	30	9	the	the	DET
dpc-2908	30	10	submental	submental	ADJ
dpc-2908	30	11	region	region	NOUN
dpc-2908	30	12	was	be	AUX
dpc-2908	30	13	observed	observe	VERB
dpc-2908	30	14	(	(	PUNCT
dpc-2908	30	15	figure	figure	NOUN
dpc-2908	30	16	2	2	NUM
dpc-2908	30	17	)	)	PUNCT
dpc-2908	30	18	while	while	SCONJ
dpc-2908	30	19	there	there	PRON
dpc-2908	30	20	was	be	VERB
dpc-2908	30	21	no	no	DET
dpc-2908	30	22	local	local	ADJ
dpc-2908	30	23	relapse	relapse	NOUN
dpc-2908	30	24	in	in	ADP
dpc-2908	30	25	the	the	DET
dpc-2908	30	26	labial	labial	ADJ
dpc-2908	30	27	region	region	NOUN
dpc-2908	30	28	.	.	PUNCT
dpc-2908	31	1	moreover	moreover	ADV
dpc-2908	31	2	,	,	PUNCT
dpc-2908	31	3	the	the	DET
dpc-2908	31	4	patient	patient	NOUN
dpc-2908	31	5	reported	report	VERB
dpc-2908	31	6	notable	notable	ADJ
dpc-2908	31	7	pain	pain	NOUN
dpc-2908	31	8	and	and	CCONJ
dpc-2908	31	9	fatigue	fatigue	NOUN
dpc-2908	31	10	reduction	reduction	NOUN
dpc-2908	31	11	.	.	PUNCT
dpc-2908	32	1	results	result	NOUN
dpc-2908	32	2	of	of	ADP
dpc-2908	32	3	laboratory	laboratory	NOUN
dpc-2908	32	4	tests	test	NOUN
dpc-2908	32	5	performed	perform	VERB
dpc-2908	32	6	before	before	ADP
dpc-2908	32	7	starting	start	VERB
dpc-2908	32	8	cemiplimab	cemiplimab	NOUN
dpc-2908	32	9	and	and	CCONJ
dpc-2908	32	10	after	after	ADP
dpc-2908	32	11	15	15	NUM
dpc-2908	32	12	weeks	week	NOUN
dpc-2908	32	13	of	of	ADP
dpc-2908	32	14	therapy	therapy	NOUN
dpc-2908	32	15	are	be	AUX
dpc-2908	32	16	reported	report	VERB
dpc-2908	32	17	in	in	ADP
dpc-2908	32	18	table	table	NOUN
dpc-2908	32	19	1	1	NUM
dpc-2908	32	20	.	.	PUNCT
dpc-2908	33	1	the	the	DET
dpc-2908	33	2	pd-1	pd-1	NOUN
dpc-2908	33	3	/	/	SYM
dpc-2908	33	4	pd	pd	ADJ
dpc-2908	33	5	-	-	PUNCT
dpc-2908	33	6	l1	l1	PROPN
dpc-2908	33	7	axis	axis	NOUN
dpc-2908	33	8	is	be	AUX
dpc-2908	33	9	involved	involve	VERB
dpc-2908	33	10	in	in	ADP
dpc-2908	33	11	the	the	DET
dpc-2908	33	12	pathogenesis	pathogenesis	NOUN
dpc-2908	33	13	of	of	ADP
dpc-2908	33	14	many	many	ADJ
dpc-2908	33	15	hematological	hematological	ADJ
dpc-2908	33	16	malignancies	malignancy	NOUN
dpc-2908	33	17	.	.	PUNCT
dpc-2908	34	1	for	for	ADP
dpc-2908	34	2	this	this	DET
dpc-2908	34	3	reason	reason	NOUN
dpc-2908	34	4	,	,	PUNCT
dpc-2908	34	5	anti	anti	ADJ
dpc-2908	34	6	-	-	ADJ
dpc-2908	34	7	pd1	pd1	ADJ
dpc-2908	34	8	drugs	drug	NOUN
dpc-2908	34	9	might	might	AUX
dpc-2908	34	10	have	have	VERB
dpc-2908	34	11	a	a	DET
dpc-2908	34	12	promising	promising	ADJ
dpc-2908	34	13	role	role	NOUN
dpc-2908	34	14	for	for	ADP
dpc-2908	34	15	their	their	PRON
dpc-2908	34	16	treatment	treatment	NOUN
dpc-2908	34	17	.	.	PUNCT
dpc-2908	35	1	in	in	ADP
dpc-2908	35	2	chronic	chronic	ADJ
dpc-2908	35	3	lymphocytic	lymphocytic	ADJ
dpc-2908	35	4	leukemia	leukemia	NOUN
dpc-2908	35	5	(	(	PUNCT
dpc-2908	35	6	cll	cll	PROPN
dpc-2908	35	7	)	)	PUNCT
dpc-2908	35	8	,	,	PUNCT
dpc-2908	35	9	pd-1	pd-1	ADV
dpc-2908	35	10	is	be	AUX
dpc-2908	35	11	expressed	express	VERB
dpc-2908	35	12	on	on	ADP
dpc-2908	35	13	cd4	cd4	PROPN
dpc-2908	35	14	+	+	PROPN
dpc-2908	35	15	  	  	SPACE
dpc-2908	35	16	and	and	CCONJ
dpc-2908	35	17	cd8	cd8	PROPN
dpc-2908	35	18	+	+	PROPN
dpc-2908	35	19	  	  	SPACE
dpc-2908	35	20	t	t	NOUN
dpc-2908	35	21	cells	cell	NOUN
dpc-2908	35	22	,	,	PUNCT
dpc-2908	35	23	and	and	CCONJ
dpc-2908	35	24	proliferation	proliferation	NOUN
dpc-2908	35	25	of	of	ADP
dpc-2908	35	26	these	these	DET
dpc-2908	35	27	cells	cell	NOUN
dpc-2908	35	28	is	be	AUX
dpc-2908	35	29	associated	associate	VERB
dpc-2908	35	30	with	with	ADP
dpc-2908	35	31	a	a	DET
dpc-2908	35	32	negative	negative	ADJ
dpc-2908	35	33	prognosis	prognosis	NOUN
dpc-2908	35	34	.	.	PUNCT
dpc-2908	36	1	in	in	ADP
dpc-2908	36	2	fact	fact	NOUN
dpc-2908	36	3	,	,	PUNCT
dpc-2908	36	4	patients	patient	NOUN
dpc-2908	36	5	with	with	ADP
dpc-2908	36	6	advanced	advanced	ADJ
dpc-2908	36	7	cll	cll	PROPN
dpc-2908	36	8	stage	stage	NOUN
dpc-2908	36	9	have	have	VERB
dpc-2908	36	10	an	an	DET
dpc-2908	36	11	increased	increase	VERB
dpc-2908	36	12	number	number	NOUN
dpc-2908	36	13	of	of	ADP
dpc-2908	36	14	pd1	pd1	NOUN
dpc-2908	36	15	+	+	NOUN
dpc-2908	36	16	 	 	SPACE
dpc-2908	36	17	cd4	cd4	PROPN
dpc-2908	36	18	+	+	PROPN
dpc-2908	36	19	 	 	SPACE
dpc-2908	36	20	t	t	NOUN
dpc-2908	36	21	cells	cell	NOUN
dpc-2908	36	22	in	in	ADP
dpc-2908	36	23	the	the	DET
dpc-2908	36	24	peripheral	peripheral	ADJ
dpc-2908	36	25	blood	blood	NOUN
dpc-2908	36	26	.	.	PUNCT
dpc-2908	37	1	pd-1	pd-1	ADP
dpc-2908	37	2	blockade	blockade	NOUN
dpc-2908	37	3	has	have	AUX
dpc-2908	37	4	also	also	ADV
dpc-2908	37	5	shown	show	VERB
dpc-2908	37	6	a	a	DET
dpc-2908	37	7	significant	significant	ADJ
dpc-2908	37	8	benefit	benefit	NOUN
dpc-2908	37	9	in	in	ADP
dpc-2908	37	10	cll	cll	PROPN
dpc-2908	37	11	patients	patient	NOUN
dpc-2908	37	12	with	with	ADP
dpc-2908	37	13	richter	richter	PROPN
dpc-2908	37	14	syndrome	syndrome	PROPN
dpc-2908	37	15	[	[	X
dpc-2908	37	16	3	3	NUM
dpc-2908	37	17	]	]	PUNCT
dpc-2908	37	18	.	.	PUNCT
dpc-2908	38	1	concerning	concern	VERB
dpc-2908	38	2	mds	mds	NOUN
dpc-2908	38	3	pathogenesis	pathogenesis	NOUN
dpc-2908	38	4	,	,	PUNCT
dpc-2908	38	5	pathological	pathological	ADJ
dpc-2908	38	6	medullary	medullary	ADJ
dpc-2908	38	7	progenitor	progenitor	NOUN
dpc-2908	38	8	cells	cell	NOUN
dpc-2908	38	9	(	(	PUNCT
dpc-2908	38	10	cd34	cd34	PROPN
dpc-2908	38	11	+	+	NOUN
dpc-2908	38	12	)	)	PUNCT
dpc-2908	38	13	,	,	PUNCT
dpc-2908	38	14	show	show	VERB
dpc-2908	38	15	an	an	DET
dpc-2908	38	16	increased	increase	VERB
dpc-2908	38	17	expression	expression	NOUN
dpc-2908	38	18	of	of	ADP
dpc-2908	38	19	checkpoint	checkpoint	NOUN
dpc-2908	38	20	molecules	molecule	NOUN
dpc-2908	38	21	,	,	PUNCT
dpc-2908	38	22	including	include	VERB
dpc-2908	38	23	pd1	pd1	NOUN
dpc-2908	38	24	,	,	PUNCT
dpc-2908	38	25	which	which	PRON
dpc-2908	38	26	interfere	interfere	VERB
dpc-2908	38	27	with	with	ADP
dpc-2908	38	28	an	an	DET
dpc-2908	38	29	effective	effective	ADJ
dpc-2908	38	30	t	t	NOUN
dpc-2908	38	31	-	-	PUNCT
dpc-2908	38	32	cell	cell	NOUN
dpc-2908	38	33	-	-	PUNCT
dpc-2908	38	34	receptor	receptor	NOUN
dpc-2908	38	35	(	(	PUNCT
dpc-2908	38	36	tcr	tcr	PROPN
dpc-2908	38	37	)	)	PUNCT
dpc-2908	38	38	signaling	signal	VERB
dpc-2908	38	39	and	and	CCONJ
dpc-2908	38	40	correct	correct	ADJ
dpc-2908	38	41	presentation	presentation	NOUN
dpc-2908	38	42	of	of	ADP
dpc-2908	38	43	the	the	DET
dpc-2908	38	44	antigens	antigen	NOUN
dpc-2908	38	45	to	to	ADP
dpc-2908	38	46	t	t	NOUN
dpc-2908	38	47	-	-	PUNCT
dpc-2908	38	48	lymphocytes	lymphocyte	NOUN
dpc-2908	38	49	.	.	PUNCT
dpc-2908	39	1	because	because	SCONJ
dpc-2908	39	2	of	of	ADP
dpc-2908	39	3	this	this	PRON
dpc-2908	39	4	,	,	PUNCT
dpc-2908	39	5	the	the	DET
dpc-2908	39	6	use	use	NOUN
dpc-2908	39	7	of	of	ADP
dpc-2908	39	8	immunotherapy	immunotherapy	NOUN
dpc-2908	39	9	is	be	AUX
dpc-2908	39	10	suggested	suggest	VERB
dpc-2908	39	11	in	in	ADP
dpc-2908	39	12	association	association	NOUN
dpc-2908	39	13	with	with	ADP
dpc-2908	39	14	demethylating	demethylate	VERB
dpc-2908	39	15	agents	agent	NOUN
dpc-2908	39	16	,	,	PUNCT
dpc-2908	39	17	such	such	ADJ
dpc-2908	39	18	as	as	ADP
dpc-2908	39	19	azacytidine	azacytidine	NOUN
dpc-2908	39	20	[	[	X
dpc-2908	39	21	4	4	NUM
dpc-2908	39	22	]	]	PUNCT
dpc-2908	39	23	.	.	PUNCT
dpc-2908	40	1	these	these	DET
dpc-2908	40	2	agents	agent	NOUN
dpc-2908	40	3	increase	increase	VERB
dpc-2908	40	4	the	the	DET
dpc-2908	40	5	expression	expression	NOUN
dpc-2908	40	6	of	of	ADP
dpc-2908	40	7	molecules	molecule	NOUN
dpc-2908	40	8	such	such	ADJ
dpc-2908	40	9	as	as	ADP
dpc-2908	40	10	cancer	cancer	NOUN
dpc-2908	40	11	/	/	SYM
dpc-2908	40	12	testis	testis	NOUN
dpc-2908	40	13	antigens	antigen	NOUN
dpc-2908	40	14	,	,	PUNCT
dpc-2908	40	15	which	which	PRON
dpc-2908	40	16	are	be	AUX
dpc-2908	40	17	highly	highly	ADV
dpc-2908	40	18	immunogenic	immunogenic	ADJ
dpc-2908	40	19	.	.	PUNCT
dpc-2908	41	1	this	this	DET
dpc-2908	41	2	synergistic	synergistic	ADJ
dpc-2908	41	3	effect	effect	NOUN
dpc-2908	41	4	might	might	AUX
dpc-2908	41	5	elicit	elicit	VERB
dpc-2908	41	6	an	an	DET
dpc-2908	41	7	increased	increase	VERB
dpc-2908	41	8	immune	immune	ADJ
dpc-2908	41	9	response	response	NOUN
dpc-2908	41	10	against	against	ADP
dpc-2908	41	11	the	the	DET
dpc-2908	41	12	pathologically	pathologically	ADV
dpc-2908	41	13	altered	alter	VERB
dpc-2908	41	14	bone	bone	NOUN
dpc-2908	41	15	marrow	marrow	NOUN
dpc-2908	41	16	progenitor	progenitor	NOUN
dpc-2908	41	17	cells	cell	NOUN
dpc-2908	41	18	of	of	ADP
dpc-2908	41	19	mds	mds	PROPN
dpc-2908	41	20	.	.	PUNCT
dpc-2908	42	1	phase	phase	NOUN
dpc-2908	42	2	2	2	NUM
dpc-2908	42	3	trials	trial	NOUN
dpc-2908	42	4	regarding	regard	VERB
dpc-2908	42	5	the	the	DET
dpc-2908	42	6	association	association	NOUN
dpc-2908	42	7	of	of	ADP
dpc-2908	42	8	demethylating	demethylate	VERB
dpc-2908	42	9	agents	agent	NOUN
dpc-2908	42	10	with	with	ADP
dpc-2908	42	11	various	various	ADJ
dpc-2908	42	12	types	type	NOUN
dpc-2908	42	13	of	of	ADP
dpc-2908	42	14	immunotherapies	immunotherapy	NOUN
dpc-2908	42	15	,	,	PUNCT
dpc-2908	42	16	including	include	VERB
dpc-2908	42	17	nivolumab	nivolumab	NOUN
dpc-2908	42	18	(	(	PUNCT
dpc-2908	42	19	an	an	DET
dpc-2908	42	20	anti	anti	NOUN
dpc-2908	42	21	-	-	ADJ
dpc-2908	42	22	pd-1	pd-1	ADJ
dpc-2908	42	23	)	)	PUNCT
dpc-2908	42	24	are	be	AUX
dpc-2908	42	25	ongoing	ongoing	ADJ
dpc-2908	42	26	,	,	PUNCT
dpc-2908	42	27	and	and	CCONJ
dpc-2908	42	28	preliminary	preliminary	ADJ
dpc-2908	42	29	results	result	NOUN
dpc-2908	42	30	seem	seem	VERB
dpc-2908	42	31	promising	promise	VERB
dpc-2908	42	32	[	[	X
dpc-2908	42	33	5	5	NUM
dpc-2908	42	34	]	]	PUNCT
dpc-2908	42	35	.	.	PUNCT
dpc-2908	43	1	in	in	ADP
dpc-2908	43	2	our	our	PRON
dpc-2908	43	3	case	case	NOUN
dpc-2908	43	4	,	,	PUNCT
dpc-2908	43	5	cemiplimab	cemiplimab	NOUN
dpc-2908	43	6	was	be	AUX
dpc-2908	43	7	successful	successful	ADJ
dpc-2908	43	8	for	for	ADP
dpc-2908	43	9	cscc	cscc	ADJ
dpc-2908	43	10	treatment	treatment	NOUN
dpc-2908	43	11	,	,	PUNCT
dpc-2908	43	12	as	as	SCONJ
dpc-2908	43	13	expected	expect	VERB
dpc-2908	43	14	.	.	PUNCT
dpc-2908	44	1	moreover	moreover	ADV
dpc-2908	44	2	,	,	PUNCT
dpc-2908	44	3	we	we	PRON
dpc-2908	44	4	suppose	suppose	VERB
dpc-2908	44	5	that	that	SCONJ
dpc-2908	44	6	cemiplimab	cemiplimab	NOUN
dpc-2908	44	7	in	in	ADP
dpc-2908	44	8	combination	combination	NOUN
dpc-2908	44	9	with	with	ADP
dpc-2908	44	10	5	5	NUM
dpc-2908	44	11	-	-	PUNCT
dpc-2908	44	12	azacytidine	azacytidine	NOUN
dpc-2908	44	13	improved	improve	VERB
dpc-2908	44	14	mds	mds	PROPN
dpc-2908	44	15	control	control	NOUN
dpc-2908	44	16	.	.	PUNCT
dpc-2908	45	1	references	reference	NOUN
dpc-2908	45	2	1	1	NUM
dpc-2908	45	3	.	.	PUNCT
dpc-2908	46	1	lai	lai	PROPN
dpc-2908	46	2	m	m	PROPN
dpc-2908	46	3	,	,	PUNCT
dpc-2908	46	4	pampena	pampena	ADJ
dpc-2908	46	5	r	r	NOUN
dpc-2908	46	6	,	,	PUNCT
dpc-2908	46	7	cornacchia	cornacchia	NOUN
dpc-2908	46	8	l	l	NOUN
dpc-2908	46	9	,	,	PUNCT
dpc-2908	46	10	et	et	PROPN
dpc-2908	46	11	al	al	PROPN
dpc-2908	46	12	.	.	PUNCT
dpc-2908	47	1	cutaneous	cutaneous	ADJ
dpc-2908	47	2	squamous	squamous	ADJ
dpc-2908	47	3	cell	cell	NOUN
dpc-2908	47	4	carcinoma	carcinoma	NOUN
dpc-2908	47	5	in	in	ADP
dpc-2908	47	6	patients	patient	NOUN
dpc-2908	47	7	with	with	ADP
dpc-2908	47	8	chronic	chronic	ADJ
dpc-2908	47	9	lymphocytic	lymphocytic	ADJ
dpc-2908	47	10	leukemia	leukemia	NOUN
dpc-2908	47	11	:	:	PUNCT
dpc-2908	47	12	a	a	DET
dpc-2908	47	13	systematic	systematic	ADJ
dpc-2908	47	14	review	review	NOUN
dpc-2908	47	15	of	of	ADP
dpc-2908	47	16	the	the	DET
dpc-2908	47	17	literature	literature	NOUN
dpc-2908	47	18	.	.	PUNCT
dpc-2908	48	1	int	int	PROPN
dpc-2908	48	2	j	j	PROPN
dpc-2908	48	3	dermatol	dermatol	NOUN
dpc-2908	48	4	.	.	PUNCT
dpc-2908	49	1	2022;61(5):548557	2022;61(5):548557	X
dpc-2908	49	2	.	.	PUNCT
dpc-2908	50	1	doi	doi	NOUN
dpc-2908	50	2	:	:	PUNCT
dpc-2908	50	3	10.1111	10.1111	NUM
dpc-2908	50	4	/	/	SYM
dpc-2908	50	5	ijd.15813	ijd.15813	NOUN
dpc-2908	50	6	.	.	PUNCT
dpc-2908	51	1	pmid	pmid	NOUN
dpc-2908	51	2	:	:	PUNCT
dpc-2908	51	3	34351635	34351635	NUM
dpc-2908	51	4	.	.	PUNCT
dpc-2908	52	1	pmcid	pmcid	NOUN
dpc-2908	52	2	:	:	PUNCT
dpc-2908	52	3	pmc	pmc	PROPN
dpc-2908	52	4	9290486	9290486	NUM
dpc-2908	52	5	.	.	PUNCT
dpc-2908	53	1	2	2	X
dpc-2908	53	2	.	.	X
dpc-2908	53	3	tam	tam	PROPN
dpc-2908	53	4	s	s	PROPN
dpc-2908	53	5	,	,	PUNCT
dpc-2908	53	6	yao	yao	PROPN
dpc-2908	53	7	cmkl	cmkl	PROPN
dpc-2908	53	8	,	,	PUNCT
dpc-2908	53	9	amit	amit	PROPN
dpc-2908	53	10	m	m	PROPN
dpc-2908	53	11	,	,	PUNCT
dpc-2908	53	12	et	et	PROPN
dpc-2908	53	13	al	al	PROPN
dpc-2908	53	14	.	.	PROPN
dpc-2908	53	15	association	association	NOUN
dpc-2908	53	16	of	of	ADP
dpc-2908	53	17	immunosuppression	immunosuppression	NOUN
dpc-2908	53	18	with	with	ADP
dpc-2908	53	19	outcomes	outcome	NOUN
dpc-2908	53	20	of	of	ADP
dpc-2908	53	21	patients	patient	NOUN
dpc-2908	53	22	with	with	ADP
dpc-2908	53	23	cutaneous	cutaneous	ADJ
dpc-2908	53	24	squamous	squamous	ADJ
dpc-2908	53	25	cell	cell	NOUN
dpc-2908	53	26	carcinoma	carcinoma	NOUN
dpc-2908	53	27	of	of	ADP
dpc-2908	53	28	the	the	DET
dpc-2908	53	29	head	head	NOUN
dpc-2908	53	30	and	and	CCONJ
dpc-2908	53	31	neck	neck	NOUN
dpc-2908	53	32	.	.	PUNCT
dpc-2908	54	1	jama	jama	PROPN
dpc-2908	54	2	otolaryngol	otolaryngol	PROPN
dpc-2908	54	3	head	head	NOUN
dpc-2908	54	4	neck	neck	NOUN
dpc-2908	54	5	surg	surg	NOUN
dpc-2908	54	6	.	.	PUNCT
dpc-2908	55	1	2020;146(2):128	2020;146(2):128	NUM
dpc-2908	55	2	-	-	PUNCT
dpc-2908	55	3	135	135	NUM
dpc-2908	55	4	doi	doi	NOUN
dpc-2908	55	5	:	:	PUNCT
dpc-2908	55	6	10.1001	10.1001	NUM
dpc-2908	55	7	/	/	SYM
dpc-2908	55	8	jamaoto	jamaoto	NOUN
dpc-2908	55	9	.2019.3751	.2019.3751	PROPN
dpc-2908	55	10	.	.	PUNCT
dpc-2908	56	1	pmid	pmid	NOUN
dpc-2908	56	2	:	:	PUNCT
dpc-2908	56	3	31804658	31804658	NUM
dpc-2908	56	4	.	.	PUNCT
dpc-2908	57	1	pmcid	pmcid	NOUN
dpc-2908	57	2	:	:	PUNCT
dpc-2908	57	3	pmc6902183	pmc6902183	NOUN
dpc-2908	57	4	.	.	PUNCT
dpc-2908	58	1	3	3	X
dpc-2908	58	2	.	.	X
dpc-2908	58	3	ding	ding	PROPN
dpc-2908	58	4	w	w	PROPN
dpc-2908	58	5	,	,	PUNCT
dpc-2908	58	6	laplant	laplant	ADJ
dpc-2908	58	7	br	br	PROPN
dpc-2908	58	8	,	,	PUNCT
dpc-2908	58	9	call	call	VERB
dpc-2908	58	10	tg	tg	PROPN
dpc-2908	58	11	,	,	PUNCT
dpc-2908	58	12	et	et	PROPN
dpc-2908	58	13	al	al	PROPN
dpc-2908	58	14	.	.	PROPN
dpc-2908	58	15	pembrolizumab	pembrolizumab	NOUN
dpc-2908	58	16	in	in	ADP
dpc-2908	58	17	patients	patient	NOUN
dpc-2908	58	18	with	with	ADP
dpc-2908	58	19	cll	cll	PROPN
dpc-2908	58	20	and	and	CCONJ
dpc-2908	58	21	richter	richter	PROPN
dpc-2908	58	22	transformation	transformation	NOUN
dpc-2908	58	23	or	or	CCONJ
dpc-2908	58	24	with	with	ADP
dpc-2908	58	25	figure	figure	NOUN
dpc-2908	58	26	1	1	NUM
dpc-2908	58	27	.	.	PUNCT
dpc-2908	59	1	(	(	PUNCT
dpc-2908	59	2	a	a	X
dpc-2908	59	3	)	)	PUNCT
dpc-2908	59	4	lower	low	ADJ
dpc-2908	59	5	left	leave	VERB
dpc-2908	59	6	hemilip	hemilip	NOUN
dpc-2908	59	7	lesion	lesion	NOUN
dpc-2908	59	8	before	before	ADP
dpc-2908	59	9	excisional	excisional	ADJ
dpc-2908	59	10	biopsy	biopsy	NOUN
dpc-2908	59	11	.	.	PUNCT
dpc-2908	60	1	(	(	PUNCT
dpc-2908	60	2	b	b	X
dpc-2908	60	3	)	)	PUNCT
dpc-2908	60	4	submental	submental	ADJ
dpc-2908	60	5	lesion	lesion	NOUN
dpc-2908	60	6	.	.	PUNCT
dpc-2908	61	1	table	table	NOUN
dpc-2908	61	2	1	1	NUM
dpc-2908	61	3	.	.	PUNCT
dpc-2908	62	1	results	result	NOUN
dpc-2908	62	2	of	of	ADP
dpc-2908	62	3	laboratory	laboratory	NOUN
dpc-2908	62	4	tests	test	NOUN
dpc-2908	62	5	performed	perform	VERB
dpc-2908	62	6	before	before	ADP
dpc-2908	62	7	starting	start	VERB
dpc-2908	62	8	cemiplimab	cemiplimab	NOUN
dpc-2908	62	9	(	(	PUNCT
dpc-2908	62	10	w0	w0	PROPN
dpc-2908	62	11	)	)	PUNCT
dpc-2908	62	12	and	and	CCONJ
dpc-2908	62	13	after	after	ADP
dpc-2908	62	14	15	15	NUM
dpc-2908	62	15	 	 	SPACE
dpc-2908	62	16	weeks	week	NOUN
dpc-2908	62	17	(	(	PUNCT
dpc-2908	62	18	w15	w15	NOUN
dpc-2908	62	19	)	)	PUNCT
dpc-2908	62	20	of	of	ADP
dpc-2908	62	21	therapy	therapy	NOUN
dpc-2908	62	22	.	.	PUNCT
dpc-2908	63	1	w0	w0	PROPN
dpc-2908	63	2	w15	w15	PROPN
dpc-2908	63	3	hemoglobin	hemoglobin	NOUN
dpc-2908	63	4	8.6	8.6	NUM
dpc-2908	63	5	g	g	NOUN
dpc-2908	63	6	/	/	SYM
dpc-2908	63	7	dl	dl	PROPN
dpc-2908	63	8	10.7	10.7	NUM
dpc-2908	63	9	g	g	NOUN
dpc-2908	63	10	/	/	SYM
dpc-2908	63	11	dl	dl	PROPN
dpc-2908	63	12	neutrophils	neutrophil	NOUN
dpc-2908	63	13	0.4	0.4	NUM
dpc-2908	63	14	x103/µl	x103/µl	PROPN
dpc-2908	63	15	0.5	0.5	NUM
dpc-2908	63	16	x103/µl	x103/µl	PROPN
dpc-2908	63	17	lymphocytes	lymphocyte	VERB
dpc-2908	63	18	0.2	0.2	NUM
dpc-2908	63	19	x103/µl	x103/µl	PROPN
dpc-2908	63	20	0.7	0.7	NUM
dpc-2908	63	21	x103/µl	x103/µl	PROPN
dpc-2908	63	22	.	.	PUNCT
dpc-2908	64	1	platelets	platelet	VERB
dpc-2908	64	2	50	50	NUM
dpc-2908	64	3	x103/µl	x103/µl	NUM
dpc-2908	64	4	74	74	NUM
dpc-2908	64	5	x	x	SYM
dpc-2908	64	6	103/µl	103/µl	NUM
dpc-2908	64	7	figure	figure	NOUN
dpc-2908	64	8	2	2	NUM
dpc-2908	64	9	.	.	X
dpc-2908	64	10	submental	submental	ADJ
dpc-2908	64	11	region	region	NOUN
dpc-2908	64	12	after	after	ADP
dpc-2908	64	13	cemiplimab	cemiplimab	NOUN
dpc-2908	64	14	treatment	treatment	NOUN
dpc-2908	64	15	.	.	PUNCT
dpc-2908	65	1	letter	letter	NOUN
dpc-2908	65	2	to	to	ADP
dpc-2908	65	3	the	the	DET
dpc-2908	65	4	editor	editor	NOUN
dpc-2908	65	5	|	|	ADV
dpc-2908	65	6	dermatol	dermatol	ADJ
dpc-2908	65	7	pract	pract	NOUN
dpc-2908	65	8	concept	concept	NOUN
dpc-2908	65	9	.	.	PUNCT
dpc-2908	66	1	2023;13(3):e2023178	2023;13(3):e2023178	NUM
dpc-2908	66	2	3	3	NUM
dpc-2908	66	3	relapsed	relapse	VERB
dpc-2908	66	4	cll	cll	PROPN
dpc-2908	66	5	.	.	PUNCT
dpc-2908	66	6	blood	blood	NOUN
dpc-2908	66	7	.	.	PUNCT
dpc-2908	67	1	2017;129(26):3419	2017;129(26):3419	X
dpc-2908	67	2	-	-	SYM
dpc-2908	67	3	3427	3427	NUM
dpc-2908	67	4	.	.	PUNCT
dpc-2908	68	1	doi	doi	NOUN
dpc-2908	68	2	:	:	PUNCT
dpc-2908	68	3	10.1182	10.1182	NUM
dpc-2908	68	4	/blood-2017	/blood-2017	SYM
dpc-2908	68	5	-	-	PUNCT
dpc-2908	68	6	02	02	NUM
dpc-2908	68	7	-	-	PUNCT
dpc-2908	68	8	765685	765685	NUM
dpc-2908	68	9	.	.	PUNCT
dpc-2908	69	1	pmid	pmid	NOUN
dpc-2908	69	2	:	:	PUNCT
dpc-2908	69	3	28424162	28424162	NUM
dpc-2908	69	4	.	.	PUNCT
dpc-2908	70	1	pmcid	pmcid	NOUN
dpc-2908	70	2	:	:	PUNCT
dpc-2908	70	3	pmc	pmc	PROPN
dpc-2908	70	4	5492091	5492091	NUM
dpc-2908	70	5	.	.	PUNCT
dpc-2908	71	1	4	4	X
dpc-2908	71	2	.	.	X
dpc-2908	71	3	wong	wong	PROPN
dpc-2908	71	4	kk	kk	PROPN
dpc-2908	71	5	,	,	PUNCT
dpc-2908	71	6	hassan	hassan	PROPN
dpc-2908	71	7	r	r	PROPN
dpc-2908	71	8	,	,	PUNCT
dpc-2908	71	9	yaacob	yaacob	NOUN
dpc-2908	71	10	ns	ns	NUM
dpc-2908	71	11	.	.	PROPN
dpc-2908	71	12	hypomethylating	hypomethylate	VERB
dpc-2908	71	13	agents	agent	NOUN
dpc-2908	71	14	and	and	CCONJ
dpc-2908	71	15	immunotherapy	immunotherapy	NOUN
dpc-2908	71	16	:	:	PUNCT
dpc-2908	71	17	therapeutic	therapeutic	ADJ
dpc-2908	71	18	synergism	synergism	NOUN
dpc-2908	71	19	in	in	ADP
dpc-2908	71	20	acute	acute	ADJ
dpc-2908	71	21	myeloid	myeloid	NOUN
dpc-2908	71	22	leukemia	leukemia	NOUN
dpc-2908	71	23	and	and	CCONJ
dpc-2908	71	24	myelodysplastic	myelodysplastic	ADJ
dpc-2908	71	25	syndromes	syndrome	NOUN
dpc-2908	71	26	.	.	PUNCT
dpc-2908	72	1	front	front	ADJ
dpc-2908	72	2	oncol	oncol	ADJ
dpc-2908	72	3	.	.	PUNCT
dpc-2908	73	1	2021	2021	NUM
dpc-2908	73	2	feb	feb	NOUN
dpc-2908	73	3	25;11:624742	25;11:624742	NUM
dpc-2908	73	4	doi	doi	NOUN
dpc-2908	73	5	:	:	PUNCT
dpc-2908	73	6	10.3389	10.3389	NUM
dpc-2908	73	7	/	/	SYM
dpc-2908	73	8	fonc.2021.624742	fonc.2021.624742	NOUN
dpc-2908	73	9	.	.	PUNCT
dpc-2908	74	1	pmid	pmid	NOUN
dpc-2908	74	2	:	:	PUNCT
dpc-2908	74	3	33718188	33718188	NUM
dpc-2908	74	4	.	.	PUNCT
dpc-2908	75	1	pmcid	pmcid	NOUN
dpc-2908	75	2	:	:	PUNCT
dpc-2908	75	3	pmc7947882	pmc7947882	NOUN
dpc-2908	75	4	.	.	PUNCT
dpc-2908	76	1	5	5	X
dpc-2908	76	2	.	.	X
dpc-2908	76	3	jelinek	jelinek	PROPN
dpc-2908	76	4	t	t	PROPN
dpc-2908	76	5	,	,	PUNCT
dpc-2908	76	6	mihalyova	mihalyova	PROPN
dpc-2908	76	7	j	j	PROPN
dpc-2908	76	8	,	,	PUNCT
dpc-2908	76	9	kascak	kascak	PROPN
dpc-2908	76	10	m	m	PROPN
dpc-2908	76	11	,	,	PUNCT
dpc-2908	76	12	duras	duras	PROPN
dpc-2908	76	13	j	j	PROPN
dpc-2908	76	14	,	,	PUNCT
dpc-2908	76	15	hajek	hajek	PROPN
dpc-2908	76	16	r.	r.	PROPN
dpc-2908	76	17	pd-1	pd-1	NOUN
dpc-2908	76	18	/	/	SYM
dpc-2908	76	19	pdl1	pdl1	ADJ
dpc-2908	76	20	inhibitors	inhibitor	NOUN
dpc-2908	76	21	in	in	ADP
dpc-2908	76	22	haematological	haematological	ADJ
dpc-2908	76	23	malignancies	malignancy	NOUN
dpc-2908	76	24	:	:	PUNCT
dpc-2908	76	25	update	update	NOUN
dpc-2908	76	26	2017	2017	NUM
dpc-2908	76	27	.	.	PUNCT
dpc-2908	77	1	immunology	immunology	NOUN
dpc-2908	77	2	.	.	PUNCT
dpc-2908	78	1	2017;152(3):357	2017;152(3):357	NUM
dpc-2908	78	2	-	-	SYM
dpc-2908	78	3	371	371	NUM
dpc-2908	78	4	.	.	PUNCT
dpc-2908	79	1	doi	doi	NOUN
dpc-2908	79	2	:	:	PUNCT
dpc-2908	79	3	10.1111	10.1111	NUM
dpc-2908	79	4	/	/	SYM
dpc-2908	79	5	imm.12788	imm.12788	NUM
dpc-2908	79	6	.	.	PUNCT
dpc-2908	80	1	pmid	pmid	NOUN
dpc-2908	80	2	:	:	PUNCT
dpc-2908	80	3	28685821	28685821	NUM
dpc-2908	80	4	.	.	PUNCT
dpc-2908	81	1	pmcid	pmcid	NOUN
dpc-2908	81	2	:	:	PUNCT
dpc-2908	81	3	pmc5629439	pmc5629439	NOUN
dpc-2908	81	4	.	.	PUNCT